NCT02539069Unknown4 期
A Post-marketing Surveillance to Evaluate the Efficacy and Safety of CHONDRON (Autologous Cultured Chondrocyte) Through Arthroscopy in Patients With Knee Cartilage Defects
适应症
试验速览
- 阶段
- 4 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- change in pain of 100mm Visual Analog Scale
研究概览
简要总结
A clinical trial to evaluate the long-term efficacy and safety of Chondron (Autologous cultured Chondrocyte) administered through arthroscopy from the drug's 48 weeks efficacy and safety evaluation with 96 weeks follow-up in patients with knee cartilage defects.
详细描述
This is an open trial, involving a total of 10 subjects. Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant. During the trial period, subjects must follow the instructions given by principal investigator. Subjects will make 8* hospital visits on a regular basis inclusive of hospitalization. During these visits subjects will be examined. For the evaluation of safety and efficacy of CHONDRON, examination with doctors, blood samples, x-ray, MRI tests, observation with the naked eyes and arthroscopy will be performed. *If tissue samples can be collected at screening visit, there will be only 7 visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with cartilage defects in their knee (Including Knee OA and Knee TA) * For a single lesion, less than 15 cm2 cartilage defects; and for multiple lesions, less than 20 cm2
- •Patients with misalignment of their tibia and femur, unstable ligament in their knee, or bony defects in the lesions of their knee, and/or who had been treated for alignment
- •Patients which surrounding cartilage are normal
- •Patients who were 15 years old or older
- •Patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form
排除标准
- •Patients hypersensitive to bovine protein
- •Patients hypersensitive to gentamicin antibiotics
- •Patients with inflammatory arthritis such as rheumatoid arthritis, gout arthritis
- •Patients with arthritis related to autoimmune disease
- •Pregnant, breast-feeding patients or those who have a possibility of pregnancy
- •Patients with accompanying diseases other than articular cartilage defects, including tumors (Exception: if the possibility of Chondron treatment is confirmed with doctor's clinical decision).
- •Patients who have a history of receiving radiotherapy, chemotherapy in the last 2 years (Exception: if the possibility of Chondron treatment is confirmed with doctor's clinical decision).
- •Patients with diabetes (however, patients whose blood sugar test results are normal and do not have any complication of diabetes, when a written opinion that CHONDRON administration is possible is appended by a doctor are excluded)
- •Patients with an infection that required hospitalization for antibiotics or the administration of antiseptic agents
- •Patients under adrenocorticoid therapy (Exception: if the possibility of Chondron treatment is confirmed with doctor's clinical decision).
- •Patients with psychiatric disorder and those who are considered to be inappropriate for this trial by the judgment of the clinical trial manager
- •Patients with cartilage defects in both knees (If the necessity of other surgery on the opposite side of knee joint using Chondron is confirmed with doctor's clinical decision).
- •Patients with liver, heart, or kidney disease (Those who show normal or insignificant test results may be enrolled in this study and receive the Chondron based on the investigator's judgment. Hypertension patients are allowed.)
- •Patients who had been infected with a virus (Those who show normal or insignificant test results may be enrolled in this study and receive the Chondron based on the investigator's judgment.)
- •Patients who had participated in another clinical trial (limited to those who participated in other studies on fracture within the last six months.)
结局指标
主要结局
change in pain of 100mm Visual Analog Scale
时间窗: 48 weeks after the surgery
The primary endpoint for the analysis is the change in the 100mmVAS at 48 weeks after the surgery compared to that at baseline.
次要结局
- Chnage of KSS(Knee Society Score)(baseline and 48 weeks after the surgery and 12, 24 and 96 weeks after the surgery)
- Chnage of ICRS(International Cartilage Repair Society) score(baseline and 48 weeks after the surgery)
- Change of MRI and mMOCART result(baseline and 48 weeks after the surgery and 12, 24 and 96 weeks after the surgery)
- change of IKDC (International Knee Documentation Committee)(baseline and 48 weeks after the surgery and 12, 24 and 96 weeks after the surgery)
- Chnage of KOOS(Knee injury and osteoarthritis outcome) score(baseline and 48weeks after the surgery and 12, 24 and 96 weeks after the surgery)
- change in pain of 100mm Visual Analog Scale(baseline and 12, 24 and 96 weeks after the surgery)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte)Traumatic ArthritisOsteoarthritisNCT02539056Sewon Cellontech Co., Ltd.24
Unknown
不适用
the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of KneeDefect of Articular CartilageArticular Cartilage Disorder of KneeArticular Cartilage, Knee DegenerationNCT02524509Sewon Cellontech Co., Ltd.50
Unknown
3 期
Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their AnkleDefect of Articular CartilageDegenerative Joint Disease of Ankle and/or FootAnkle (Ligaments); Instability, FamilialNCT02537067Sewon Cellontech Co., Ltd.28
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164
Unknown
不适用
Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUSDegenerative Joint Disease of KneeOsteoarthritis, KneeNCT05348525Yooyoung Pharmaceutical Co., Ltd.54